Keywords
How to Cite
Abstract
Patients with oncohematological or primary hematological diseases have a higher risk of developing severe forms of COVID-19 and their evolution is unfavorable. General care and immunization with vaccines is the current form of protection for these patients. The presence of post-vaccination IgG antibodies was analyzed in 73 oncohematological adult patients or with immune diseases treated at a regional hospital in Argentina. The patients were immunized with the Sputnik V, AstraZeneca or Sinopharm vaccine. 69% were evaluated after one dose and the rest after two. We observed that 65% of the patients achieved IgG seroconversion. In the analysis of the variables that influenced seroconversion with achieved levels >65% were: age <60 years: 67%; no chemotherapy treatment at the time of analysis: 69%; complete remission of the disease: 67%; two doses: 68% and history of COVID-19 infection prior to vaccination: 83%. However, none of these variables showed a statistically significant difference in a univariate analysis. The anti-SARS-Cov2 vaccination in these patients showed a significant tendency to seroconversion, the main factor being COVID-19 infection prior to vaccination.
References
Gavillet M, Carr Klappert J, Spertini O et al. Acute leukemia in the time of COVID-19. Leuk Res. 2020 Mar 26;92:106353.
He W, Chen L, Chen L et al. COVID-19 in persons with haematological cancers. Leukemia. 2020 Jun;34(6):1637-1645.
Zhou P, Yang XL, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270-273.
Liu STH, Lin HM, Baine I et al. Convalescent plasma treatment of severe COVID-19: a propensity scorematched control study. Nat. Med. 2020;26:1708-1713.
Okba NMA et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26:1478-1488.
Khoury DS, Cromer D, Reynaldi A et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27:1205-1211.
Wajnberg A, Mansour M, Leven E et al. Humoral immune response and prolonged PCR positivity in a cohort of 1343 SARS-CoV 2 patients in the New York City region. medRxiv 2020.04.30.20085613.
Wu J, Liang B, Chen C et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. Nat Commun. 2021;12:1813.
Hartley GE, Edwards ESJ, Aui PM et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. Sci Immunol. 2020 Dec 22;5(54):eabf8891.
Dan JM, Mateus J, Kato Y et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371:6529.
Chenguang S, Zhaoqin W, Fang Z et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323:1582-1589.
John RT, Donna LF et al. COVID-19 vaccines: modes of immune activation and future challenges. Nat Rev Immunol. 2021 Apr;21(4):195-197.
Mathew D, Giles JR, Baxter AE et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science. 2020 Sep 4;369(6508):eabc8511.
Stadlbauer D, Amanat F, Chromikova V et al. SARSCoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol. 2020;57,e100.
Von Rhein C, Scholz T, Henss L et al. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma. J Virol Methods. 2021 Feb;288:114031.
Herzog Tzarfati K, Gutwein O, Apel A et al. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies. Am J Hematol. 2021 Oct 1;96(10):1195-1203.
Pimpinelli F, Marchesi F, Piaggio G et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. Journal of Hematology & Oncology. 2021;14(1):81.
Daniel A, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127 (20):2391-2405.
Herishanu Y, Avivi I, Aharon A et al. Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. Blood. 2021;137(23):3165-3173.
Logunov DY, Dolzhikova IV et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397:671-81.
Voysey M, Costa Clemens S A et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine. (AZD1222) against SARS-CoV-2: an interim analysis of four randomized controlled trials in Brazil, South Africa and the UK. Lancet. 2021;397:99-111.
22. Folegatti PM, Ewer KJ, Aley PK et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine
against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. Lancet. 2020 Aug 15;396(10249):467-478.
Shengli X, Yuntao Z, Yanxia W et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021 Jan;21(1):39-51.
Jeewandara C, Aberathna I S, Pushpakumara P D et al. Antibody and T cell responses to Sinopharm/BBIBPCorV in naïve and previously infected individuals in Sri Lanka. medRxiv 2021.07.15.21260621.
Ojeda DS, González López Ledesma MM, Pallarés HM et al. Emergency response for evaluating SARSCoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog. 2021 Jan
;17(1):e1009161. 26. Rossi AH, Ojeda DS, Varese A et al. Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose. Cell Reports Medicine. 2021 Aug 17;2(8):100359.
All material published in the journal HEMATOLOGÍA (electronic and print version) is transferred to the Argentinean Society of Hematology. In accordance with the copyright Act (Act 11 723), a copyright transfer form will be sent to the authors of approved works, which has to be signed by all the authors before its publication. Authors should keep a copy of the original since the journal is not responsible for damages or losses of the material that was submitted. Authors should send an electronic version to the email: revista@sah.org.ar